Medical Condition News

RSS

Latest updates in clinical practice decision-making in cancer care presented at NCCN 17th conference

The National Comprehensive Cancer Network (NCCN) held the NCCN 17th Annual Conference: Clinical Practice Guidelines & Quality Cancer Care, March 14 - 18 at The Westin Diplomat in Hollywood, Florida. The latest updates in clinical practice decision-making in cancer care were presented, including, but not limited to, the new NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Lung Cancer Screening and updates to the NCCN Guidelines for Melanoma and Non-Hodgkin's Lymphomas.

29 Mar 2012

Lilly's ixekizumab Phase II trial on plaque psoriasis meets primary endpoint

New Phase II data, published today in the New England Journal of Medicine, showed that Eli Lilly and Company's ixekizumab, an anti-IL-17 monoclonal antibody, met its primary endpoint in patients with moderate-to-severe plaque psoriasis, with significantly more patients achieving at least a 75 percent improvement in Psoriasis Area and Severity Index (PASI) scores from baseline (PASI 75) compared with placebo at week 12.

29 Mar 2012

BMI not linked with either surgical complications or esophageal cancer patient survival

Researchers at Moffitt Cancer Center in Tampa, Fla., have found - contrary to previous studies linking inferior outcomes in patients with gastrointestinal malignancies to higher body mass index (BMI) - that in their study of BMI and negative outcomes, there was no such link. They concluded that BMI was not associated with either surgical complications or esophageal cancer patient survival.

29 Mar 2012

Enrolment complete in Veloxis LCP-Tacro Phase III study in de novo kidney transplant patients

Veloxis Pharmaceuticals A/S today announced that enrolment has been completed in its pivotal LCP-Tacro Phase III study in de novo kidney transplant patients. The LCP-Tacro 3002 study is designed to demonstrate non-inferiority versus the gold standard therapy Prograf and has randomized over 540 patients at approximately 90 clinical sites around the world.

29 Mar 2012

Papillary renal cell carcinoma patients face low tumour re-occurrence and cancer-related death rates

Patients with papillary renal cell carcinoma, the second most common kidney cancer subtype, face a low risk of tumour recurrence and cancer-related death after surgery. Those are the key findings of a multi-centre study of nearly 600 patients published in the April issue of the urology journal BJUI.

29 Mar 2012

Rare total shoulder replacement performed using rotator cuff sparing approach

On Tuesday, March 6, 2012, Ryan Simovitch, M.D., Board Certified and fellowship trained orthopedic surgeon, performed one of the first successful total shoulder replacements with a rotator cuff sparing technique in South Florida. Jupiter Medical Center remains on the leading edge of orthopedics, offering orthopedic surgeons, state-of-the-art facilities, and comprehensive rehabilitation services to help patients return to an active and healthy lifestyle.

29 Mar 2012

Albumin best choice for prevention of circulatory dysfunction in cirrhotic patients

Administration of albumin reduces morbidity and mortality in cirrhotic patients undergoing large-volume paracentesis due to severe ascites, according to a new meta-analysis published online today in Hepatology, the official journal of the American Association for the Study of Liver Diseases.

29 Mar 2012

COPD Foundation to lead DRIVE4COPD campaign

The successful national campaign to increase public awareness of COPD changed organizational leadership effective March 23, 2012. Led since inception by Boehringer Ingelheim Pharmaceuticals Inc., a leader in developing medicines to treat COPD, the DRIVE4COPD campaign will now be led by the COPD Foundation, a not-for-profit organization dedicated to the education, early diagnosis, research and enhanced therapy for people with lives impacted by COPD.

29 Mar 2012

Ember adds Joslin's BMP7 technology to brown fat intellectual property portfolio

Ember Therapeutics, Inc., a company harnessing breakthroughs in brown fat biology and insulin sensitization to revolutionize the treatment of metabolic disease, today announced the completion of an agreement with the Joslin Diabetes Center to exclusively license intellectual property covering bone morphogenetic protein 7 (BMP7), which has been shown to play a role in the regulation of brown fat development.

29 Mar 2012

BMI not associated with esophageal cancer patient survival

29 Mar 2012

CRT, EIF create £50M Cancer Research Technology Pioneer Fund

Cancer Research Technology, (CRT) Cancer Research UK's commercial arm, and the European Investment Fund (EIF) have joined together to create a £50M investment fund to bridge the funding gap in the UK between cancer drug discovery and early development.

29 Mar 2012

Positive results from Nile's cenderitide Phase 1 trial on chronic heart failure

Nile Therapeutics, Inc., a biopharmaceutical company that develops novel therapeutics for heart failure patients, today announced results from its recently completed Phase 1 clinical trial evaluating the pharmacokinetics (PK), pharmacodynamics (PD), safety and tolerability of subcutaneous bolus and subcutaneous infusion of cenderitide in patients with chronic heart failure.

29 Mar 2012

FDA extends review period for Almirall and Forest Labs' aclidinium bromide NDA

Forest Laboratories, Inc. and Almirall, S.A. announced today that the U.S. Food and Drug Administration (FDA) will require a three-month extension to complete its review of the data supporting the New Drug Application (NDA) for aclidinium bromide, a new long-acting antimuscarinic for the maintenance treatment of Chronic Obstructive Pulmonary Disease.

29 Mar 2012

One-side parathyroid surgery has poorer long-term outcomes

Dr James Norman, MD and his partners at the Norman Parathyroid Center have published a landmark study in this week's Journal of the American College of Surgeons describing how the operation they developed and advocated for more than 19 years has significantly poorer long-term outcomes. The unilateral or "one-side" parathyroid surgical procedure to remove parathyroid tumors from patients suffering from hyperparathyroidism is a dramatic change from the large neck operation that it replaced.

29 Mar 2012

Greenwood launches Syndromic Autism 62-Gene Panel

RainDance Technologies, Inc., the Digital Biology Company, today announced that Greenwood Genetic Center has commercially launched its Syndromic Autism 62-Gene Panel which was built for use on RainDance's picodroplet-based targeted sequencing platform.

29 Mar 2012

SafeStitch Medical's AMID Stapler to be presented at AHS 2012

SafeStitch Medical, Inc. will present the AMID Stapler® at the 5th International Hernia Congress in New York City, March 28-31, 2012.

29 Mar 2012

Daiichi Sankyo, NGM to discover and develop new treatments for diabetes

Daiichi Sankyo Company, Ltd. and NGM Biopharmaceuticals, Inc. announced today that they have entered into a research collaboration and license agreement to discover and develop novel therapeutics that modulate beta-cell regeneration for the treatment of diabetes.

29 Mar 2012

Obstacles standing in the way of cancer prevention

More than half of all cancer is preventable, and society has the knowledge to act on this information today, according to Washington University public health researchers at the Siteman Cancer Center in St. Louis.

29 Mar 2012

Study calls for re-examination of criteria used to prioritize liver transplant candidates

Patients with end-stage liver disease complicated by the most common type of liver cancer - hepatocellular carcinoma (HCC) - are less likely to die or become too sick for a transplant while waiting for a new liver than those with other complications of end-stage liver disease, according to new research from the Perelman School of Medicine at the University of Pennsylvania.

29 Mar 2012

New McMaster centre to track health differences by ethnicity

Tracking health differences by ethnicity is the cornerstone of the new Chanchlani Research Centre at McMaster University.

29 Mar 2012

Medical Condition News

Latest updates in clinical practice decision-making in cancer care presented at NCCN 17th conference

Lilly's ixekizumab Phase II trial on plaque psoriasis meets primary endpoint

BMI not linked with either surgical complications or esophageal cancer patient survival

Enrolment complete in Veloxis LCP-Tacro Phase III study in de novo kidney transplant patients

Papillary renal cell carcinoma patients face low tumour re-occurrence and cancer-related death rates

Rare total shoulder replacement performed using rotator cuff sparing approach

Albumin best choice for prevention of circulatory dysfunction in cirrhotic patients

COPD Foundation to lead DRIVE4COPD campaign

Ember adds Joslin's BMP7 technology to brown fat intellectual property portfolio

BMI not associated with esophageal cancer patient survival

CRT, EIF create £50M Cancer Research Technology Pioneer Fund

Positive results from Nile's cenderitide Phase 1 trial on chronic heart failure

FDA extends review period for Almirall and Forest Labs' aclidinium bromide NDA

One-side parathyroid surgery has poorer long-term outcomes

Greenwood launches Syndromic Autism 62-Gene Panel

SafeStitch Medical's AMID Stapler to be presented at AHS 2012

Daiichi Sankyo, NGM to discover and develop new treatments for diabetes

Obstacles standing in the way of cancer prevention

Study calls for re-examination of criteria used to prioritize liver transplant candidates

New McMaster centre to track health differences by ethnicity

The Proteoform Puzzle: Unlocking the Next Frontier

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Latest News